---
title: "Baxter's shares fall as 2026 profit guidance disappoints. Q4 EPS at 44 cents, sales reach $2.974 billion, up 8% yoy."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275794905.md"
description: "Baxter International Inc. (NYSE: BAX) shares fell as the company reported a Q4 adjusted EPS of 44 cents, below management's guidance of 52-57 cents and Wall Street's estimate of 54 cents, due to an unfavorable product mix. However, Q4 sales reached $2.974 billion, an 8% year-over-year increase, exceeding the consensus of $2.824 billion. The Medical Products & Therapies segment contributed approximately $1.39 billion, reflecting a 6% increase on a reported basis."
datetime: "2026-02-12T18:10:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275794905.md)
  - [en](https://longbridge.com/en/news/275794905.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275794905.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275794905.md) | [繁體中文](https://longbridge.com/zh-HK/news/275794905.md)


# Baxter's shares fall as 2026 profit guidance disappoints. Q4 EPS at 44 cents, sales reach $2.974 billion, up 8% yoy.

Baxter International Inc. (NYSE: BAX) is currently trading near the lower end of its 52-week range between $17.4 and $37.74, as per data from Benzinga Pro. In the fourth quarter, Baxter reported an adjusted EPS of 44 cents, falling short of both the management guidance range of 52-57 cents and the Wall Street estimate of 54 cents. This decrease was mainly attributed to an unfavorable product mix. The company achieved sales of $2.974 billion in the quarter, marking an 8% increase year over year on a reported basis and a 3% increase on an operational basis, surpassing the consensus of $2.824 billion. Management had initially anticipated a 2% growth in fourth-quarter sales on a reported basis and a 2% decline on an operational basis. Medical Products & Therapies segment sales accounted for around $1.39 billion, showing a 6% increase on a reported basis and a 4% increase on an operational basis.

### Related Stocks

- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Baxter International Inc. (BAX.US)](https://longbridge.com/en/quote/BAX.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [Geoffrey Beran Rose Sells 7,732 Shares of Pulmonx (NASDAQ:LUNG) Stock](https://longbridge.com/en/news/277978473.md)
- [Pulmonx Q4 revenue beats expectations](https://longbridge.com/en/news/277833961.md)
- [Enovis Corporation $ENOV Shares Sold by Royce & Associates LP](https://longbridge.com/en/news/277474498.md)
- [J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma](https://longbridge.com/en/news/278091420.md)
- [/C O R R E C T I O N -- Johnson & Johnson/ | JNJ Stock News](https://longbridge.com/en/news/277699503.md)